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Objectives. Overactive bladder (OAB) is a chronic disease, but comparative trials of anticholinergics, which are commonly used
for treatment of OAB, have generally been performed for up to 12 weeks only. There is no comparative study of a long-term
intervention.Methods.Weconducteda52-weekprospectiverandomizedcomparativestudytoevaluatetheeﬃcacyandtolerability
of two anticholinergics. Results. Forty-one Japanese patients with untreated OAB were randomly assigned to imidafenacin and
solifenacin groups. There was no diﬀerence in OABSS and KHQ scores between the two groups, but the severity and incidence
of adverse events caused by the anticholinergics showed increased diﬀerences between the groups with time. The severity of dry
mouth and the incidence of constipation were signiﬁcantly lower in the imidafenacin group (P = 0.0092 and P = 0.0013, resp.).
Conclusions. This study is the ﬁrst long-term trial to show diﬀerences in the properties of anticholinergics that were not detected
in short-term studies. Since OAB is a chronic disease, we conclude that imidafenacin is preferable to solifenacin from a perspective
of safety.
1.Background
Overactive bladder (OAB) is a syndrome deﬁned by symp-
toms of urinary urgency with or without urge incontinence,
and usually with frequency and nocturia [1]. The incidence
of OAB ranges from 10% to 20% in Europe and the United
States [2, 3]. The incidence in people aged ≥40 years old
in Japan is 12.4%; that is, approximately 8.1 million people
suﬀer from OAB. OAB is strongly correlated with age and the
incidence in elderly people (≥70 years old) exceeds 30% [4].
OAB reduces quality of life (QOL) and is a signiﬁcant health
problem [5].
The major treatment for OAB is pharmacotherapy,
and anticholinergics (muscarinic receptor antagonists) are
recommended as the ﬁrst option. However, these drugs
act on muscarinic receptors throughout the body and may
cause adverse events such as dry mouth and constipation
[6]. Imidafenacin and solifenacin were introduced in Japan
in 2006 and 2007, respectively. Both drugs have excellent
selectivity for the bladder over the salivary gland [7–11].
Several comparative trials of anticholinergics have been
performed, but these have generally used a study period
of up to 12 weeks [12–22]. Therefore, the long-term drug
tolerability needs to be evaluated in an actual clinical
situation because OAB is a chronic disease. It is important
for clinicians to understand the pharmacological proﬁles
of drugs for OAB and to choose a drug based on a
long-term perspective. Therefore, we conducted a 52-week
prospective randomized comparative study to evaluate the
eﬃcacy and tolerability of imidafenacin and solifenacin as
novel anticholinergics for OAB.2 Advances in Urology
Week
Visit 12 3 4 5 6 7
40 4 1 2 2 8 4 0 5 2
Study period
(Screening) (Baseline)
Run-in
4weeks
Imidafenacin 0.1 mg × 2times/day
Solifenacin 5mg/day
(Randomaization)
=OABSS,KHQ, adverse events (dry mouth,constipation, and
blurred vision)
=Residual urine volume, QT interval, and
urine ﬂow test (Qmax and each urination volume, urination time)
Figure 1: Design of the LIST study.
2. Methods
2.1. Ethics. This study was performed as a prospective, open,
randomized, parallel-group trial to compare the long-term
eﬃcacy and tolerability of imidafenacin and solifenacin in
Japanese patients with new OAB. The study was conducted
in accordance with the Helsinki Declaration after approval
of the Kanto Rosai Hospital Ethics Committee. Before
enrollment in the study, the objectives and methods of the
study and other necessary issues related to protection of
human rights were explained to the patients. All patients
gave written informed consent on a voluntary basis prior to
enrollment in the study.
2.2. Subjects. Patients were enrolled in this study from
January to December 2009 and followed up until December
2010. The subjects were male and female patients aged ≥50
and <80 years old who were diagnosed with OAB based on
theiroveractivebladdersymptomscore(OABSS:0–15range,
with a higher score indicating a severer condition) and had
not been treated with any anticholinergics. Patients with a
score for urinary urgency of ≥2 points and a total OABSS of
≥3points wereenrolledinthe study. The otherinclusion cri-
teria were symptoms for at least 4 weeks and untreated OAB.
The exclusion criteria were a history of pharmacotherapy
of OAB; complications of diseases contraindicated for anti-
cholinergics (serious heart disease, untreated angle-closure
glaucoma, myasthenia gravis, gastric outlet and intestinal
obstruction, paralytic ileus, and gastric and intestinal atony)
residual urine volume ≥100mL (determined by abdominal
sonography); strong possibility of prostate and bladder
cancer; acute active urinary tract infection; a patient judged
n o tt ob ee l i g i b l eb ya ni n v e s t i g a t o ri nc h a r g e .
2.3. Study Design. The study design is shown in Figure 1.
Patients who gave informed consent were observed for
4 weeks to conduct tests for establishment of baseline
data. Patients who met all the inclusion criteria and did
not meet an exclusion criterion were randomly assigned
to the imidafenacin or solifenacin group. Patients in the
imidafenacin group took a 0.1mg tablet of imidafenacin
twice a day after breakfast and supper. Patients in the
solifenacin group took a 5mg tablet of solifenacin after
breakfast. The administration period was scheduled to be 52
weeks and patients who took imidafenacin and solifenacin
for at least 12 weeks were included in the eﬃcacy analysis.
Random assignment to groups was performed by the central
registration system in the pharmacy, and age and sex were
used as factors in the assignment.
Similar drugs for urinary frequency, urinary inconti-
nence, and OAB anticholinergics (tolterodine, propiverine,
oxybutynin, and ﬂavoxate), cholinergics, and any drug
under development for which the eﬀects were not clariﬁed
were not allowed during the study period to avoid eﬀects
of concomitant drugs on the eﬃcacy evaluation of the
investigational drugs and for the safety of the subjects. An
alpha-1 blocker was allowed as a concomitant drug with the
limitation that a speciﬁc drug was used without a change
in dosage and administration and was not replaced with
another drug during the study period (observation and
treatment phase). Urologic and genital surgery, catheteriza-
tion, intermittent urethral catheterization, and electric and
magnetic stimulation therapy were also restricted during the
study period.
2.4. Evaluation of Eﬃcacy and Tolerability. Age, sex, body
weight, history of OAB, residual urine volume, urine ﬂow
test, prostate volume and electrocardiography (ECG) were
evaluated at the start of the observation period as back-
ground data.
The primary endpoint for eﬃcacy was the change in
OABSS from baseline. The primary endpoints for safety were
the 3 adverse events caused by anticholinergics: dry mouth,
constipation, and blurred vision. The severity of dry mouth
was evaluated on a 3-point scale: mild, barely noticeable;
moderate, tolerable after drinking water; severe, intolerable
after drinking water, leading to discontinuation of the
investigational drug. The investigators determined whether
a patient had constipation or blurred vision based on a face-
to-face interview. Constipation was evaluated subjectively by
the patients themselves and this information was obtained
during consultation. Patients with constipation received oral
drugs. Similarly to constipation, visual impairment was
subjectivelyevaluatedbypatientsthemselvesduringvisitsfor
consultation.
The secondary endpoints for eﬃcacy were changes
in OABSS components from baseline (daytime frequency,
nighttime frequency, urgency, and urgency incontinence)
and the King’s Health Questionnaire (KHQ) score. The
KHQ is a QOL questionnaire that is speciﬁc for urinary
incontinence and has been translated into several languages,
including Japanese. The secondary endpoints for safety were
adverse events, laboratory tests, blood pressure, pulse rate,
urine ﬂow test, residual urine volume, and 12-lead ECG
(QT interval). The residual urine volume was determined
by abdominal sonography immediately after urination. The
prostate volume was calculated based on transabdominal
ultrasound ﬁndings at the time of enrollment in the study.Advances in Urology 3
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Figure 2: Summary of patient ﬂow in the LIST study.
Eﬃcacy and safety were evaluated at 6 measurement
points: at the end of the observation period, and 4, 12, 28,
40, and 52 weeks after the beginning of the treatment period.
Residual urine volume, urine ﬂow test (Qmax, urination
volume, urination time), and 12-lead ECG were determined
at the end of the observation period, and 4, 12, and 52 weeks
afterthebeginningofthetreatmentperiod.Theinvestigators
conducted an interview using the OABSS and KHQ at every
visit. Drug compliance was conﬁrmed by the patients them-
selves at every visit. If a patient requested discontinuation
of the drug during consultation, the investigator interviewed
the patient to determine the reason. If a patient did not visit
the hospital, the reason was determined by telephone.
2.5. Statistical Analysis
(1) Eﬃcacy Analysis. The eﬃcacy analysis set consisted
of patients who took imidafenacin and solifenacin for at
least 12 weeks, excluding ineligible patients and patients
who received a restricted concomitant drug or therapy.
Descriptive statistics for eﬃcacy endpoints (values, amounts
and rates of change) were calculated for each measurement
point. Changes in the mean ± standard deviation (SD) or
mean alone were plotted by group on a graph with the value
on the y-axis and time on the x-axis. Descriptive statistics for
values and changes in QOL score were calculated for each
measurement point and changes (mean ± SD) from the end
of the observation period are shown as a ﬁgure. Statistical
analysis was performed by Wilcoxon test for intragroup
comparison and by Mann-Whitney U test for intergroup
comparison.
(2) Safety Analysis. The safety analysis set consisted of
patients who took imidafenacin and solifenacin at least
once and for whom information for safety was available
after administration. The incidence of adverse events caused
by anticholinergics (dry mouth, constipation, and blurred
vision) was evaluated by Fisher Exact test and the severity of
dry mouth was evaluated by Mann-Whitney U test. Kaplan-
Meier curves for the time to the ﬁrst adverse event caused
by anticholinergics were evaluated by logrank test. Residual
urine volume and QT interval were evaluated by Wilcoxon
test. The signiﬁcance level was set at 0.05.
3. Results
The details of the patients are shown in Figure 2. A total
of 41 patients with untreated OAB who visited our hospital
from January to December 2009 and gave informed consent
were enrolled in the study, with 21 and 20 randomly assigned
to the imidafenacin and solifenacin groups, respectively.
Consequently, the safety analysis set consisted of 41 patients.
The short-term eﬃcacy analysis set consisted of 35
patients (83.3%) who continuously took imidafenacin or
solifenacin for at least 12 weeks, including 17 in the imidafe-
nacin group and 18 in the solifenacin group. The long-
term eﬃcacy analysis set consisted of 25 patients (62.5%)
who continuously took imidafenacin or solifenacin for 524 Advances in Urology
Table 1: Baseline characteristics of subjects for short-term analysis set.
Demographics Imidafenacin Solifenacin P-value
Subjects 17 18
Age (years) (Mean ± SD) 70.2 ±6.56 9 .8 ±7.70 .8697a
<60, n (%) 0 (0%) 1 (5.6%)
≥60, n (%) 8 (47.1%) 6 (33.3%)
≥70, n (%) 9 (52.9%) 11 (61.1%)
Gender
Male, n (%) 10 (58.8%) 12 (66.7%) 0.7332b
Female, n (%) 7 (41.2%) 6 (33.3%)
OABSS (total score) (Mean ± SD) 8.0 ±2.08 .7 ±2.40 .2989c
Severity of OABSS
Mild, n (%) 2 (11.8%) 3 (16.7%) 1.0000c
Moderate, n (%) 15 (88.2%) 14 (77.8%)
Severe, n (%) 0 (0%) 1 (5.6%)
Postvoid residual volume (mL) (Mean ± SD) 14.2 ±15.11 3 .5 ±11.40 .8814a
Each urination volume (mL) (Mean ± SD) 141.7 ±109.9 187.9 ±160.80 .3312a
Urination time (second) (Mean ± SD) 28.3 ±19.82 7 .4 ±9.90 .8749a
Qmax (mL/s) (Mean ± SD) 12.1 ±7.41 4 .2 ±10.60 .4925a
In male
Prostate volume (mL) (Mean ± SD) 22.7 ±11.62 5 .3 ±9.40 .5661a
Use of α1b l o c k e r ,n (%) 9 (90%) 9 (75%) 0.8328b
Severity of OAB was deﬁned as total OABSS score ≤5: mild; 6 to ≤11: moderate; ≥12: severe
a: Unpaired t-test, b: Fisher’s exact test, c: Mann-Whitney U test, two-sided. SD: standard deviation.
weeks, including 11 in the imidafenacin group and 14 in the
solifenacin group. There was no signiﬁcant diﬀerence in the
rate of treatment completion between the two groups (P =
0.2477). Six patients (14.3%) in the imidafenacin group and
4 (9.5%) in the solifenacin group took the drug continuously
for at least 12 weeks, but for less than 52 weeks. Among these
patients, discontinuation occurred through patient choice
due to remission of OAB symptoms in 3 (7.1%) in the
imidafenacingroup,andduetoseveredrymouthin1(2.4%)
a n dl a c ko fe ﬃcacy in 2 (4.8%) in the solifenacin group.
Other reasons for discontinuation were similar in the two
groups.
The background of the 35 patients who took an inves-
tigational drug for at least 12 weeks and were included in
the short-term eﬃcacy analysis is shown in Table 1.T h e r e
was no signiﬁcant diﬀerence in age, sex, OABSS at baseline
(8.0 ± 2.0 versus 8.7 ± 2.4), and percentage of cases with
moderate severity (15/17, 88.2% versus 14/17, 77.8%) in
the imidafenacin and solifenacin groups. The score for each
of the 4 OABSS components also did not diﬀer between
the groups (data not shown). There was also no diﬀerence
in residual urine volume, voiding volume, voiding time,
maximum urine ﬂow rate (Qmax), QT interval, prostate
volume in male patients, and frequency of administration of
alpha blockers between the groups.
Thebackgroundofthe25patientswhotookaninvestiga-
tional drug for 52 weeks and were included in the long-term
eﬃcacy analysis is shown in Table 2. Among these patients,
there were no signiﬁcant diﬀerences in background factors
and OABSS at baseline (9.0 ± 1.3 versus 8.9 ± 2.4) in the
imidafenacin and solifenacin groups.
3.1. Eﬃcacy. Eﬃcacy over 12 weeks was evaluated in the
short-term eﬃcacy analysis set of 35 patients. Changes in
the total OABSS in this set are shown in Figure 3.C h a n g e s
in the total OABSS in the long-term eﬃcacy analysis set of
25 patients are shown in Figure 4. The results of eﬃcacy
analysis showed no signiﬁcant diﬀerence in eﬃcacy between
imidafenacin and solifenacin for treatment over 12 weeks
and 52 weeks. With regard to changes in OABSS components
from baseline, the score for the number of urination events
atnight at52weeksafterthebeginning oftreatmentchanged
by −0.6 ± 0.7 in the imidafenacin group and by 0.1 ± 0.8 in
the solifenacin group, with a signiﬁcant diﬀerence between
the groups. No other OABSS component scores diﬀered
signiﬁcantly between the two groups at any measurement
point (data not shown).
Changes in scores for KHQ domains relative to those
at baseline in the 35 patients in the short-term eﬃcacy
set and the 25 patients in the long-term eﬃcacy set are
shown in Figures 5 and 6,r e s p e c t i v e l y .C h a n g e si ns c o r e s
for domains on the KHQ (a QOL questionnaire speciﬁc for
urinary incontinence) from baseline did not diﬀer between
the two groups at 12 and 52 weeks. Thus, the results of this
study showed that imidafenacin and solifenacin had similar
eﬃcacy for OAB for both a short period of 12 weeks and a
long period of 52 weeks.Advances in Urology 5
Table 2: Baseline characteristics of subjects for long-term analysis set.
Demographics Imidafenacin Solifenacin P-value
Subjects 11 14
Age (years) (Mean ± SD) 69.9 ±6.77 1 .4 ±6.00 .5560a
<60, n (%) 0 (0%) 0 (0%)
≥60, n (%) 4 (36.4%) 4 (28.6%)
≥70, n (%) 7 (63.6%) 10 (71.4%)
Gender
Male, n (%) 7 (63.6%) 10 (71.4%) 1.0000b
Female, n (%) 4 (36.4%) 4 (28.6%)
OABSS (total score) (Mean ± SD) 9.0 ±1.38 .9 ±2.60 .8453c
Siverity of OABSS
Mild, n (%) 0 (0%) 3 (21.4%) 0.3671c
Moderate, n (%) 11 (100%) 10 (71.4%)
Severe, n (%) 0 (0%) 1 (7.1%)
Postvoid residual volume (mL) (Mean ± SD) 15.1 ±14.71 3 .4 ±11.00 .7487a
Each urination volume (mL) (Mean ± SD) 125.3 ±85.0 203.8 ±179.80 .1654a
Urination time (second) (Mean ± SD) 29.1 ±23.02 6 .1 ±10.70 .6939a
Qmax (mL/s) (Mean ± SD) 11.2 ±8.81 4 .8 ±11.80 .4120a
In male
Prostate volume (mL) (Mean ± SD) 21.0 ±9.12 7 .8 ±8.20 .1302a
Use of α1b l o c k e r ,n (%) 6 (85.7%) 9 (90.0%) 1.0000b
Severity of OAB was deﬁned as total OABSS score ≤5: mild; 6 to ≤11: moderate; ≥12: severe
a: Unpaired t-test, b: Fisher’s exact test, c: Mann-Whitney U test, two-sided. SD: standard deviation.
3.2. Safety and Tolerability. The tolerability of imidafenacin
and solifenacin was good. Adverse events occurred in 76.2%
of patients in the imidafenacin group and 95.0% in the
solifenacin group. One patient discontinued solifenacin due
to severe dry mouth whereas there was no case of discon-
tinuation of imidafenacin for this reason. The incidence of
dry mouth over 52 weeks was 71.4% in the imidafenacin
group and 90% in the solifenacin group, with no signiﬁcant
diﬀerence between the groups. However, severe dry mouth
was observed in 4 patients (20%) in the solifenacin group,
but in no patients in the imidafenacin group. Furthermore,
the cases of dry mouth in the imidafenacin group were
signiﬁcantly milder than those in the solifenacin group
(Mann-Whitney U test: P = 0.0092). The overall severity of
dry mouth was also signiﬁcantly milder in the imidafenacin
group throughout the study period (Table 3). The incidence
of constipation over 52 weeks was also signiﬁcantly lower in
the imidafenacin group (14.3% versus 65.0%, Table 3). The
incidence of blurred vision for 52 weeks did not diﬀer sig-
niﬁcantly between the groups (9.5% versus 35.0%, Table 3)
and there were no adverse events related to blood pressure
andpulserateinthetwogroups.Kaplan-Meiercurvesforthe
time to the ﬁrst adverse event caused by anticholinergics are
shown in Figure 7. There was no diﬀerence in the incidence
of moderate or severe dry mouth between the groups in
the 12-week analysis (logrank test: P = 0.0616, data not
shown), but this incidence diﬀered signiﬁcantly in the 52-
week analysis (Log Rank test: P = 0.0412; Figure 7). There
was also no diﬀerence in the incidence of constipation
betweenthetwogroupsinpatientswhotookimidafenacinor
solifenacin for at least 12 weeks (Log Rank test: P = 0.0621,
data not shown). However, the incidence in patients who
took either drug for 52 weeks was signiﬁcantly higher in the
solifenacin group (Log Rank test: P = 0.0017). There was
no signiﬁcant diﬀerence in the incidence of blurred vision in
patients who took the drug for at least 12 weeks (Log Rank
test: P = 0.3749, data not shown) or continuously for 52
weeks (Log Rank test: P = 0.0686).
ChangesintheresidualurinevolumeandQTintervalare
shown in Tables 4 and 5, respectively. Signiﬁcant increases
in the residual urine volume occurred in both groups at
12 weeks compared to baseline. No increase in the residual
urine volume from baseline occurred in the imidafenacin
group at 52 weeks, but a signiﬁcant increase was found in
the solifenacin group. There was no signiﬁcant diﬀerence
between the two groups, and no patient had more than
100mL of residual urine volume in either group. No
signiﬁcant change in QT interval was observed throughout
the study period in either group. Furthermore, although
the results of urine ﬂow tests (Qmax, urination volume,
and urination time) slightly changed in both groups, no
signiﬁcant changes were found after 12 and 52 weeks.
4. Discussion
This study is the ﬁrst prospective randomized comparative
study of the eﬃcacy and tolerability of anticholinergics
for a period of 52 weeks in patients with OAB. Previous
comparative studies of anticholinergics have used a study
period of up to 12 weeks [12–22], but OAB is a chronic6 Advances in Urology
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Figure 3: Changes in OABSS in the short-term analysis set. The
endpoint is presented as a mean ± standard deviation. Intragroup
comparison (versus the end of the observation period) by Wilcoxon
test,
∗∗∗P < 0.001. Intergroup comparison by Mann-Whitney U
test, NS: not signiﬁcant.
disease and there is a need to examine the long-term eﬃcacy
andtolerabilityofdrugsusedtotreatOAB.Theresultsofthis
study suggest that anticholinergics should be chosen based
on long-term eﬃcacy and safety. As expected, we found no
signiﬁcant diﬀerence in OABSS and KHQ scores between
the imidafenacin and solifenacin groups. The incidence of
dry mouth in the 12-week analysis was 16.9% whereas that
in the 52-week analysis was 39.2%, which emphasizes the
importance of evaluating long-term safety. The severity of
dry mouth was milder at a dose of 0.2mg/day imidafenacin
than at 5mg/day solifenacin, and intergroup diﬀerences in
the severity of dry mouth increased with time.
Imidafenacin and solifenacin are novel anticholinergics
for OAB that were designed to have excellent selectivities for
the bladder over the salivary gland and for the M3 receptor
that controls contraction of bladder smooth muscle. The
eﬃcacy and tolerability of imidafenacin (0.2mg/day) and
solifenacin (5mg and 10mg/day) were shown in a 12-week
phase III double blind comparative trial performed in Japan
with propiverine (20mg/day) as a control [20, 22]. With
regard to safety, the incidence and severity of dry mouth was
signiﬁcantly lower at a dose of 0.2mg/day imidafenacin than
at 20mg/day propiverine, and the incidence of constipation
was also lower. The incidence of dry mouth was also
signiﬁcantly lower at 5mg/day solifenacin, but signiﬁcantly
higher at 10mg/day solifenacin, in comparison with that at
20mg/day propiverine; and the incidence of constipation
was signiﬁcantly higher at 10mg/day solifenacin than at
20mg/day propiverine. Consequently, the regular dose of
solifenacin was set at 5mg/day.
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Figure 4: Changes in OABSS in the long-term analysis set. The
endpoint is presented as a mean ± standard deviation. Intragroup
comparison (versus the end of the observation period) by Wilcoxon
test,
∗∗P < 0.01,
∗∗∗P < 0.001. Intergroup comparison by Mann-
Whitney U test, NS: not signiﬁcant.
Table 3: Distribution of major anticholinergic adverse events in
each group over 52 weeks.
Variable, n (%) Imidafenacin Solifenacin P-value
N (safety population) 21 20
Dry mouth 15 (71.4%) 18 (90.0%) 0.2379b
Mild 8 (38.1%) 4 (20.0%)
Moderate 7 (33.3%) 10 (50.0%) 0.0092a
Severe 0 (0%) 4 (20.0%)
Constipation 3 (14.3%) 13 (65.0%) 0.0013b
Blurred vision 2 (9.5 %) 7 (35.0%) 0.0670b
The severity of dry mouth was evaluated on a 3-point scale: mild, barely
noticeable; moderate, tolerable after drinking water; severe, intolerable after
drinking water, leading to discontinuation of the investigational drug;
a: Mann-Whitney U test, b: Fisher exact test, two-sided.
Based on these previous reports, 0.2mg/day imidafe-
nacin and 5mg/day solifenacin were used as the doses in
this study. This choice was made for several reasons. First,
most patients are treated at a low initial dose in practice and
20% to 30% subsequently require an increased dose. Second,
there is a possibility that the frequency of the increase in dose
could diﬀer between the two groups, if an increase in dose is
allowed. Third, comparison of a low dose with less adverse
events is reasonable in evaluation of long-term tolerability.
In a 12-week phase III trial in Japan, the incidence
of constipation with 5mg/day solifenacin was 10.6%, and
did not diﬀer from thatwith 0.2mg/day imidafenacin orAdvances in Urology 7
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Figure 5: Mean changes in KHQ domain scores from baseline to endpoint in the short-term analysis set. The endpoint is presented as a
mean. Intergroup comparison by Mann-Whitney U test, NS: not signiﬁcant. Intragroup comparison (versus the end of the observation
period) by Wilcoxon test,
∗P < 0.05,
∗∗P < 0.01.
Table 4: Changes in residual urine volume and QT interval in the short-term analysis set.
Variable Imidafenacin Solifenacin
Number of subjects 17 18
Residual urine volume (mL)
0 week (Mean ± SD) 14.2 ±15.11 3 .5 ±11.4
4 week (Mean ± SD) 29.3 ±26.2
∗∗ 40.8 ±33.2
∗∗ NS
12 week (Mean ± SD) 37.7 ±32.7
∗∗ 29.4 ±28.1
∗ NS
QT interval (ms)
0 week (Mean ± SD) 414.8 ±20.7 423.2 ±21.8
4 week (Mean ± SD) 415.5 ±16.5 423.5 ±19.0N S
12 week (Mean ± SD) 415.0 ±16.4 423.6 ±23.5N S
Intragroup (versus 0 weeks: the end of the observation period)
Paired t-test ∗: P<0.05, ∗∗: P<0.01
Intergroup: unpaired t-test, NS: not signiﬁcant, SD: standard deviation.
20mg/day propiverine [22]. In 52-week administration,
the incidences were 9.9% and 19.0% with imidafenacin
[23] and 5mg/day solifenacin [24], respectively; that is,
approximately double those in the phase III trial. These
results suggest that constipation is an adverse event of
anticholinergics of similar importance to dry mouth. Meek
et al. recently conducted meta-analysis on the relationship
between constipation and anticholinergics in OAB patients
and found that the risk for constipation doubled in patients
treated with anticholinergics for at least 2 weeks. The odds8 Advances in Urology
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Figure 7: Kaplan-Meier curves for the time to the ﬁrst adverse event caused by the anticholinergic agent (52 weeks).Advances in Urology 9
Table 5: Changes in residual urine volume and QT interval in the long-term analysis set.
Variable Imidafenacin Solifenacin
Number of subjects 11 14
Residual urine volume (mL)
0 week (Mean ± SD) 15.1 ±14.71 3 .4 ±11.0
4 week (Mean ± SD) 30.9 ±20.4
∗ 38.6 ±32.1
∗∗ NS
12 week (Mean ± SD) 30.7 ±28.03 0 .6 ±27.7
∗ NS
52 week (Mean ± SD) 20.6 ±25.43 1 .1 ±23.4
∗∗ NS
QT interval (ms)
0 week (Mean ± SD) 413.6 ±24.6 426.9 ±22.4
4 week (Mean ± SD) 415.8 ±18.9 426.2 ±20.1N S
12 week (Mean ± SD) 416.4 ±18.4 427.2 ±23.0N S
52 week (Mean ± SD) 417.0 ±20.3 424.4 ±22.5N S
Intragroup (versus 0 weeks: the end of the observation period)
Paired t-test ∗: P<0.05, ∗∗: P<0.01
Intergroup: Unpaired t-test, NS: not signiﬁcant, SD: standard deviation.
Table 6: Overactive Bladder Symptom Score (OABSS)∗.
Question Frequency Score
How many times do you typically urinate from waking in the morning until sleeping at night? ≤7 0
8–14 1
≥15 2
How many times do you typically wake up to urinate from sleeping at night until waking in the morning? 0 0
1 1
2 2
≥3 3
How often do you have a sudden desire to urinate, which is diﬃcult to defer? Not at all 0
Less than once a
week
1
Once a week or
more
2
About once a
day
3
2–4 times a day 4
5t i m e sad a yo r
more
5
How often do you leak urine because you cannot defer the sudden desire to urinate? Not at all 0
Less than once a
week
1
Once a week or
more
2
About once a
day
3
2–4 times a day 4
5t i m e sad a yo r
more
5
∗Patients were instructed to circle the score that best applied to their urinary condition during the past week; the overall score was the sum of the four scores.
ratios were 3.0 for solifenacin, 2.9 for trospium, 2.3 for
oxybutynin, 2.1 for fesoterodine, 1.9 for darifenacin, and
1.4 for tolterodine. Thus, the risk for constipation diﬀered
b e t w e e nd r u g s ,a n dt h i sv a r i a t i o nm a yd e p e n do nd i ﬀerences
in aﬃnity for muscarinic receptors among the drugs [25].
The diﬀerent incidences of adverse events with imidafe-
nacin and solifenacin might be due to diﬀerences in pharma-
cokinetics between the two drugs. In mouse and rat, Yamada
et al. found that anticholinergics had diﬀerent organ-speciﬁc
aﬃnity for muscarinic receptors [26–29]. Solifenacin has10 Advances in Urology
Table 7: The King’s Health Questionnaire (KHQ).
KHQ question Signiﬁcant content
(1) How would you evaluate your health today? Health
(2) How much do you think your bladder problem hampers your life? Bladder problems,
hampering your life
(3) Frequency: do you go the bathroom too often? Frequency going to the
bathroom
(4) Nocturia: do you get up at night to urinate? Nocturia, getting up
(5) Urgency: do you feel urgency to urinate and have diﬃculty
controlling it? Urinary urgency
(6) Hyperactive bladder: do you lose urine when you feel urgency to
urinate? Hyperactive bladder
(7) Urinary incontinence by exertion: do you lose urine during physical
activities?
Urinary incontinence,
physical activities
(8) Nocturnal enuresis: do you wet your bed at night? Nocturnal enuresis
(9) Incontinence during sexual intercourse: do you lose urine during
sexual intercourse?
Incontinence during sexual
intercourse
(10) Frequent infections: do you have many urinary infections? Urinary infections
(11) Pain in the bladder: do you feel pain in the bladder? Pain in the bladder
(12) Do you have any other problem related to your bladder? Problem related to your
bladder
(13) How intensely do your bladder problems hinder your house chores?
(cleaning, washing, and cooking, etc.)
House chores (cleaning,
washing, cooking, etc.)
(14) How intensely do your bladder problems hinder your work or your
daily activities outside the house? (shopping, taking children to school,
etc.)
Work, daily activities
outside the house
(shopping, taking children
to school, etc.)
(15) Do your bladder problems hinder your physical activities?
(walking, running, or any other sport?)
Physical activities (walking,
running, or any other
sport)
(16) Do your bladder problems hinder you when you want to travel? Travelling
(17) Do your bladder problems hinder you when go to the church, a
meeting, a party? Church, meeting, and party
(18) Do you avoid visiting friends because of your bladder problems? Visiting friends
(19) Do your bladder problems hinder your sexual life? Sex life
(20) Do your bladder problems hinder your life with your
partner/husband? Partner/husband
(21) Do your bladder problems disturb your family members? Disturbing family members
(22) Do you feel depressed with your bladder problems? Depression
(23) Do you feel anxious or nervous with your bladder problems? Anxious, nervous
(24) Do you feel bad about yourself because of your bladder problems? Feeling bad about yourself
(25) Do your bladder problem hinder your sleep? Sleep
(26) Do you use any kind of hygienic protection such as diapers, pads,
or lining to keep yourself dry? Hygienic protection
(27) Do you control the amount of liquids you drink? Controlling the amount of
liquids, drinking
(28) Do you need to change your underwear (panties) when you get wet? Changing underwear
(29) Do you worry about smelling like urine? Smelling of urine
a long half-life and binds to muscarinic receptors in not only
the bladder but also the salivary gland and colon for an
extended period [26], which reduces salivation and intestinal
peristaltic movement and results in severe dry mouth and
constipation. In contrast, imidafenacin has a short half-life
and does not bind to muscarinic receptors in the colon [29],
accounting for the low incidence of constipation. However,
imidafenacinbindstomuscarinicreceptorsinthebladderfor
a relatively long time, despite the short blood half-life [29].
A limitation of this study is the small-scale single-center
design. However, conducting the study at a single institution
also excludes interobserver variability and variation betweenAdvances in Urology 11
institutions, and this improves the reliability of the results.
We emphasize that this clinical trial was performed under
conditions seen in actual clinical practice. In daily practice,
unlike in trials of new drug development, a physician must
respect a patient’s request and this leads to frequent changes
in treatment plans. The reasons for drug discontinuation
were surveyed by telephone or interview, and we found that
the persistence of drug use in the study was good compared
to previous reports of actual clinical practice. Thus, Wagg
et al. found that the persistence was relatively low for most
antimuscarinics after 12 months (27.1–36.3%, including
oxybutynin, solifenacin, tolterodine, and trospium) [30].
There were 10 dropout patients in the current study, since
35 patients took either drug for at least 12 weeks and were
included in the eﬃcacy analysis set, but only 25 of these
patients took a drug continuously for 52 weeks (Figure 2).
Of these 10 patients, 6 were in the imidafenacin group and
4 in the solifenacin group. However, the reason for discon-
tinuation was remission of OAB symptoms in 3 patients in
the imidafenacin group, reﬂecting a positive eﬀect of the
drug. The other 3 patients in this group discontinued the
trial due to onset of neurogenic bladder caused by cerebral
infarction(acausalrelationshipbetweentheonsetofcerebral
infarction and imidafenacin was excluded) in 1 case and
frequentvisitsforanotherdiseasein2cases;thus,noneofthe
patients who discontinued imidafenacin did so for negative
reasons associated with the drug. In contrast, 2 patients
discontinued solifenacin due to the absence of an eﬀect and
one patient discontinued due to a severe adverse reaction
to solifenacin; thus, 3 patients discontinued solifenacin for
negative reasons. The 6 patients who took imidafenacin or
solifenacin for less than 12 weeks and were not included in
the eﬃcacy analysis did not discontinue for negative reasons.
There was no diﬀerence in the percentage of patients who
received continuous treatment in the two groups, and these
data rule out the possibility that the apparent eﬃcacy in the
52-week analysis was due to dropout of patients in whom the
drugs were ineﬀective. The possibility that dropout patients
inﬂuencedtheresultsofthelong-termanalysiswasalsoruled
out because dropout for adverse events occurred only in the
solifenacin group.
Imidafenacin and solifenacin were both developed to
reduce adverse events caused by anticholinergics. The results
of this study indicate that long-term tolerability to imidafe-
nacin is superior to that for solifenacin while there was no
diﬀerence in eﬃcacy between the two groups. We note that
the doses of both drugs can be increased, and therefore
further studies should be conducted to compare long-term
tolerability at higher doses. Drugs with novel mechanisms,
including β3 receptor agonists, are also currently under
development for treatment of OAB, and trials to evaluate
the long-term eﬃcacy and tolerability of these drugs will be
important since OAB is a QOL-related disease.
5. Conclusions
This study is the ﬁrst long-term trial to show diﬀerences in
the properties of anticholinergics that could not be detected
in short-term studies. Imidafenacin and solifenacin were
both eﬀective for OAB, but the incidence of adverse events
with imidafenacin was signiﬁcantly lower than that with
solifenacin. There were also time-dependent diﬀerences in
the severity and incidence of adverse events. Since OAB
is a chronic disease, we conclude that treatment with
imidafenacin is preferable to solifenacin from a perspective
of safety.
Appendix
See Tables 6 and 7,[ 31, 32].
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